Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Azacitidine clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Azacitidine as a study intervention. Browse Azacitidine recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
225
Shown on this page
12
Local indexed summaries
225
Local recruiting
54
The trial list below is retrieved from the live ClinicalTrials.gov search API for Azacitidine. Results on this page are currently sorted by Recently updated.

Filter and sort this therapy

These controls apply only within Azacitidine. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 1–12 of 225 matching trials for Azacitidine.
Indexed local directory records.

Top conditions

Acute Myeloid Leukemia 68 Myelodysplastic Syndrome 28 Myelodysplastic Syndromes 28 Chronic Myelomonocytic Leukemia 23 Leukemia 14 Refractory Acute Myeloid Leukemia 14

Top sponsors

M.D. Anderson Cancer Center 27 National Cancer Institute (NCI) 21 Celgene 6 Novartis Pharmaceuticals 6 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 6 AbbVie 5

Top locations

Houston, Texas 89 New York, New York 70 Chicago, Illinois 64 Boston, Massachusetts 58 Los Angeles, California 52 Dallas, Texas 44

Indexed official records

Open in full search
Recruiting Phase 2 Interventional

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT06317649
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
219
States / cities
Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 175 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 7:27 PM EDT
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
335
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 258 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 12:57 AM EDT
Recruiting Phase 2 Interventional

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

NCT05554406
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
211
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 171 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 12:57 AM EDT
Recruiting Phase 3 Interventional

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

NCT05183035
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Cytarabine, Fludarabine, Gemtuzumab Ozogamicin, Venetoclax
Drug
Lead sponsor
PedAL BCU, LLC
Other
Eligibility
29 Days to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 12:34 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

NCT06445907
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Q702, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 19, 2026, 7:48 PM EDT
Recruiting Phase 2 Interventional

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

NCT05554393
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
167
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 136 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 20, 2026, 7:27 PM EDT
Recruiting Phase 2 Interventional

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

NCT05401097
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biopsy, Enasidenib, Ivosidenib, Venetoclax
Drug · Procedure
Lead sponsor
Alice Mims
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Columbus, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 18, 2026, 5:13 AM EDT
Recruiting Phase 3 Interventional

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

NCT07007312
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Azacitidine (AZA), Cytarabine (Ara-C), Daunorubicin, Placebo, Venetoclax, Ziftomenib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
38
States / cities
Gilbert, Arizona • Clovis, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 18, 2026, 4:03 AM EDT
Recruiting Phase 3 Interventional

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

NCT06465953
View directory record Official record
Conditions
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
Interventions
Azacitidine, Ivosidenib
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 1:18 AM EDT
Recruiting Phase 3 Interventional

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Azacitidine (AZA), Bleximenib, Placebo, Venetoclax (VEN)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
48
States / cities
Birmingham, Alabama • Goodyear, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 19, 2026, 6:21 AM EDT
Recruiting Phase 1 Interventional

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT06177067
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Interventions
Azacitidine, Cytarabine, Methotrexate, Revumenib, Venetoclax, intrathecal (IT) chemotherapy
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
San Diego, California • Aurora, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 20, 2026, 1:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

NCT04588922
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
SLS009, azacitidine, venetoclax
Drug
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • Goodyear, Arizona • Duarte, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 20, 2026, 1:27 PM EDT

About this Azacitidine clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Azacitidine as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Azacitidine.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Azacitidine.